Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

IMMX vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Captures Overall Composite Edge (53.1 HOLD vs 38.7 SELL), While COCP Leads 3–2 on Growth & Valuation Pillars

IMMX Overall Winner 6-Pillar Tally: IMMX 2 – 3 COCP (1 Tie) Matrix Metrics: IMMX 5 – 2 COCP

As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (53.1/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Balance Sheet & Cash Flow), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. IMMX trades at $7.20 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.01 (N/M Forward P/E, -3063.6% operating margin).

  • Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (53.1/100 HOLD vs. COCP 38.7/100 SELL) and 1.83β · 83% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMMX vs COCP
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.20
-3.74% 1D
Market Cap $657.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.83β · 83% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $7.96 · SMA50: $9.57
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.3% 1D
Market Cap $18.9M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 0.98β · 54% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $1.00 · SMA50: $1.07

6-Pillar Scorecard Institutional Category Breakdown (IMMX 2 – 3 COCP)

Columns: Metric · IMMX · COCP
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 47.3x
2. Growth & Scale COCP
Revenue Growth (YoY) +0.0% +26.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $330,000
Market Cap $657.1M $18.9M
3. Profitability & Quality IMMX
Gross Margin N/A N/A
Operating Margin 0.0% -3063.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -27.0% -311.7%
4. Balance Sheet & Cash Flow IMMX
Cash Generation (TTM) -$39M -$7.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage $224M Net Cash $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning COCP
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 49.3% (9th %ile) N/A (N/A)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMMX (5) vs COCP (2)
Institutional Metric IMMX COCP Criterion Row Edge
Market Capitalization
Scale
$657.1M $18.9M Larger Scale IMMX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +26.9% Higher Growth COCP
Operating Margin (TTM)
Profitability
0.0% -3063.6% Higher Margin IMMX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-27.0% -311.7% Higher ROE IMMX
52-Week Range Position
Momentum
32% ($4–$15) 20% ($1–$2) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
1.83β · 83% Vol 0.98β · 54% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
53.1 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
N/A $330,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 47.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$39M ($224M Net Cash) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +19.11 pp
IMMX: -12.41% · COCP: +6.7%
3M Horizon COCP +33.62 pp
IMMX: -45.41% · COCP: -11.79%
6M Horizon COCP +6.57 pp
IMMX: -18.74% · COCP: -12.17%
1Y Horizon IMMX +72.96 pp
IMMX: +71.02% · COCP: -1.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs COCP. Trailing 12-month operating profitability (IMMX 0.0% vs COCP -3063.6%) and valuation multiples (IMMX N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M
COCP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$330,000
Gross MarginN/A
Op. Margin-3063.6%
ROE / Fwd P/E-311.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMMX BREAKDOWN
59d in phase · OBV DISTRIBUTION
Current IV 49.3%
IV Percentile 9th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $657.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $18.9M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMMX vs COCP Key Questions & Quantitative Answers

As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (53.1/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Balance Sheet & Cash Flow), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. IMMX trades at $7.20 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.01 (N/M Forward P/E, -3063.6% operating margin). Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (53.1/100 HOLD vs. COCP 38.7/100 SELL) and 1.83β · 83% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COCP leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus $330,000 for COCP. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

COCP screens cheaper on headline valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus COCP (-311.7% ROE) capital efficiency.

In options market volatility and institutional positioning, IMMX carries 49.3% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.83β · 83% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.